Ładuje się......
Budget impact model of avelumab in patients with metastatic merkel cell carcinoma in the US
Objective: To estimate the budget impact of avelumab as a treatment option for patients with treatment-naïve first-line (1L) and previously treated second-line or later (2L+) metastatic Merkel cell carcinoma (mMCC) in the US. Methods: A budget impact model was developed to evaluate the addition of a...
Zapisane w:
| Wydane w: | Clinicoecon Outcomes Res |
|---|---|
| Główni autorzy: | , , , |
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
Dove
2019
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6535410/ https://ncbi.nlm.nih.gov/pubmed/31190927 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S202642 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|